Active Ingredient(s):Alogliptin + Pioglitazone FDA Approved: * January 25, 2013 Pharm Company: *TAKEDA PHARMS USA Category:Diabetes
Alogliptin, sold under the brand names Nesina and Vipidia,) is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class. Alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination wi...
* May have multiple approval dates, manufacturers, or labelers.